Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.59 |
| ▸ | FLT3 | P36888 | 10/20 | 0.59 |
| ▸ | FLT4 | P35916 | 9/20 | 0.59 |
| ▸ | CSF1R | P07333 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 9/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1097598 | 0.94 | PDGFRB (0.65) | PDGFRBFLT3FLT4CSF1RKDM4E | |
| SCHEMBL1099584 | 0.94 | PDGFRB (0.59) | PDGFRBFLT3FLT4CSF1RKDM4E | |
| SCHEMBL1099153 | 0.87 | PDGFRB (0.59) | PDGFRBFLT3FLT4CSF1RKDR | |
| SCHEMBL1098052 | 0.86 | PDGFRB (0.60) | PDGFRBFLT3FLT4CSF1RMAPK10 | |
| SCHEMBL20788539 | 0.84 | KMT2A (0.64) | PDGFRBFLT3FLT4CSF1RKDR | |
| SCHEMBL2176128 | 0.81 | MET (0.64) | PDGFRBFLT3FLT4CSF1RKDM4E | |
| SCHEMBL1099781 | 0.81 | PDGFRB (0.59) | PDGFRBFLT3FLT4CSF1RKDR | |
| SCHEMBL1719352 | 0.81 | PDGFRB (0.65) | PDGFRBFLT3FLT4CSF1RKDR | |
| SCHEMBL4670135 | 0.81 | KDR (0.74) | PDGFRBFLT4CSF1RKDRPDGFRA | |
| SCHEMBL1099216 | 0.80 | PDGFRB (0.66) | PDGFRBFLT3FLT4CSF1RMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | claimed |
| EP-1802591-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-01-11 | — | — | EP | claimed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | claimed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | claimed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | claimed |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2012-06-28 | — | — | US | disclosed |
| US-8153643-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-20090233924-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2009-09-17 | — | — | US | disclosed |
| EP-1802591-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040520-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233924-A1 | Quinazoline derivatives | AQP1, PGF, F12 | PDGFRB 700/4885FLT3 117/4885FLT4 10/4885 |
| US-20120165351-A1 | QUINAZOLINE DERIVATIVES | AQP1, F12, AQP3 | PDGFRB 1056/4885FLT3 126/4885FLT4 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.